Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Abstract Background The emergent outbreak of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for therapeutic opportunities to overcome this pandemic. Ivermectin is an antiparasitic drug that has shown effectivenes...

Full description

Bibliographic Details
Main Authors: Anan Manomaipiboon, Kittisak Pholtawornkulchai, Sujaree Poopipatpab, Swangjit Suraamornkul, Jakravoot Maneerit, Wiroj Ruksakul, Uraporn Phumisantiphong, Thananda Trakarnvanich
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Trials
Subjects:
Efficacy
Ivermectin
COVID-19
Randomized controlled trial
SARS-CoV-2
RT-PCR
Online Access:https://doi.org/10.1186/s13063-022-06649-3

Internet

https://doi.org/10.1186/s13063-022-06649-3

Similar Items